Solazyme Announces Pricing of Initial Public Offering

May 27, 2011

For Immediate Release

SOUTH SAN FRANCISCO, California (May 27, 2011) — Solazyme, Inc., a renewable oil and bioproducts company, today announced the pricing of its initial public offering of 10,975,000 shares of common stock at a price to the public of $18.00 per share. Of the shares of common stock in the offering, Solazyme is offering 10,375,000 shares, and selling stockholders are offering 600,000 shares. In addition, Solazyme has granted the underwriters a 30-day option to purchase up to an additional 1,646,250 shares of common stock, solely to cover over-allotments, if any. Solazyme will not receive any proceeds from the sale of shares by the selling stockholders.

Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Jefferies & Company, Inc. is acting as lead manager, and Pacific Crest Securities LLC and Lazard Capital Markets LLC are acting as co-managers. The shares will begin trading on the NASDAQ Global Select Market on May 27, 2011 under the ticker symbol “SZYM.”

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on May 26, 2011. Any offer or sale will be made solely by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Morgan Stanley & Co. Incorporated,

Attn: Prospectus Department, 180 Varick Street, New York, NY 10014; or Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Solazyme

Solazyme, Inc. is a renewable oil company and a leader in industrial biotechnology. Founded in 2003 and headquartered in South San Francisco, Solazyme’s proprietary technology transforms a range of low-cost plant-based sugars into high-value oils. Our renewable products can replace or enhance oils derived from the world’s three existing sources—petroleum, plant and animal fats. We tailor the composition of our oils to address specific customer requirements, offering superior performance characteristics at a competitive cost to conventional oils. Solazyme's oils and fuels provide compelling solutions to increasingly complex issues of fuel scarcity, energy security and environmental impact while fitting into the pre-existing multi-trillion dollar fuel infrastructure. Solazyme's investors, among others, include Braemar Energy Ventures, Harris & Harris Group, Lightspeed Venture Partners, The Roda Group, VantagePoint Venture Partners, and Zygote Ventures. For more information, please visit www.solazyme.com.

For more information

Genet Garamendi
VP, Corporate Communications
(650) 963-5228
press@solazyme.com

About Braemar Energy Ventures

Braemar Energy Ventures is a venture capital fund making early- to mid-stage investments in the energy technology sector. The firm's principals have invested in more than 60 companies in the sector and have more than 100 years of combined technical, operational and financial experience in energy and energy-related industries. Braemar partners with exceptional companies and management teams, in both alternative and traditional energy markets, that can contribute to a more profitable and efficient energy landscape through innovation and marketplace expertise. Additional information is available at BraemarEnergy.com or on Twitter at twitter.com/braemarenergy or @BraemarEnergy.

For more information

Alison McIntyre
Prosek Partners
(212) 279-3115 x269
amcintyre@prosek.com